Rani Bansal, MD @DrRaniBansal X Profile

Rani Bansal, MD

@DrRaniBansal

Followers

689

Following

1K

Media

71

Statuses

287

@DukeCancer breast oncologist, former Chief oncology fellow @brownUcancer #bcsm

Joined August 2021

Don't wanna be here? Send us removal request.

Rani Bansal, MD

@DrRaniBansal

2 days

Excited to discuss updates in breast cancer treatment! Join @RadiologyACR for the upcoming #AIRP Breast Imaging Course Nov. 7-8! Experience a virtual in-depth review of #breastimaging with a multidisciplinary team. Learn more and register today:

acr.org

Experience an in-depth review of breast imaging with a multidisciplinary team, providing a holistic approach to breast cancer treatment and management.

1

4

Erika Hamilton, MD, FASCO

@ErikaHamilton9

13 days

DB-05 press release reporting significant improvement in IDFS with T-DXd vs. T-DM1 for residual HER-2 #bcsm after neoadjuvant therapy. Presentation in presidential session at #ESMO25. #myESMOAmbassadors https://t.co/tdXUUIx5ng

astrazeneca.com

1

12

40

Toni Choueiri, MD

@DrChoueiri

17 days

Wait, whaaaaaaaaaat???? It is confirmed. DESTINY-Breast05 will be at #ESMO25 ! LBA1 - Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with HER2+ Breast Cancer with residual invasive disease after neoadjuvant therapy Presenter: Charles Geyer (@upmc)

Toni Choueiri, MD

@DrChoueiri

17 days

The #ESMO25 Presidential are out--check them: @FAndreMD @MyriamChalabi @myESMO

1

33

124

Yakup Ergün

@dr_yakupergun

30 days

Vitamin B12 for prophylaxis of capecitabine-associated hand–foot syndrome 💥Oral methylcobalamin reduced capecitabine-related HFS in HER2-negative early BC, with no added safety concerns 💬A simple prophylaxis option to support treatment adherence https://t.co/khCOH0RDv7

3

112

297

Erika Hamilton, MD, FASCO

@ErikaHamilton9

2 months

Adjuvant abemaciclib improves overall survival in monarchE. 👏 #bcsm #CDK4/6 https://t.co/suJZaJkaf1

investor.lilly.com

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

8

14

52

Duke Center for Brain and Spine Metastasis

@DukeMets

2 months

Thrilled to team up this season to spread awareness. Thank you for being champions for these amazing patients! 💙

Duke Field Hockey

@DukeFH

2 months

Thank you @DukeMets for stopping by yesterday to educate us more on brain & spine metastasis! Please visit their table on Sept. 7, when we host Maryland to learn more. #DukeTrue

0

4

10

Duke Center for Brain and Spine Metastasis

@DukeMets

2 months

New in @NatureMedicine's News & Views: A HER3-targeting antibody-drug conjugate for leptomeningeal metastasis. Check out the invited commentary on the phase 2 TUXEDO-3 trial by Carey Anders, MD, @DrRaniBansal, & @DrVanSwearingen https://t.co/3LGXnIQZzV

0

3

6

Rani Bansal, MD

@DrRaniBansal

2 months

We need to keep pushing the field forward for better options for our patients with LMD! @CareyAnders1 @DrVanSwearingen @DukeMets @DukeCancer https://t.co/7R2InqsBGd

1

0

4

Dr Sarah Sammons

@drsarahsam

4 months

Recent rationale in metastatic breast cancer for bringing ADCs into the 1st line has quoted very high 1st line attrition rates of patients not making it to second line. This study is likely more accurate of 2025 patients. In total, 9% of patients with MBC do not make it to

5

17

68

Heather Moore

@HeatherMoore16

4 months

After recurrence, the median duration of first-line metastatic treatment was 3.0 months (IQR 1.6-5.0 months)…we need to identify best systemic therapy options for those recurring on adjuvant CDK4/6i!

Chiara Corti

@CCortiMD

4 months

Pleased to share the first series of pts who experienced recurrence on adjuvant abemaciclib+ET: ➤ 9.2% (15/163) recurred ➤ 50% ER loss post-tx ➤ 90% TP53-pathway alterations post-tx ➤ Median 1L m+ tx duration: 3.0 mo (IQR 1.6–5.0) https://t.co/5Jpzq8uyc2

3

2

1

Matteo Lambertini, MD PhD

@matteolambe

4 months

Oral abstract early #BreastCancer session at #ASCO25: do we really need #carboplatin with neoadjuvant #taxane #trastuzumab #pertuzumab in #HER2+ disease? Very promising findings but survival outcomes are needed @OncoAlert @ASCO #bcsm

2

13

25

Rani Bansal, MD

@DrRaniBansal

4 months

Very exciting!!! We need new drugs especially in mTNBC and especially post topo-1 ADCs as they move further up in our treatment paradigm

Erika Hamilton, MD, FASCO

@ErikaHamilton9

4 months

Particularly excited about the activity in #TNBC post topo-1 ADCs. 86% had seen savituzumab govitecan, 1/3 had seen T-DXd, 1/4 had seen both! #ASCO25 #ADC #NewTargetNewPayload

0

2

4

Rani Bansal, MD

@DrRaniBansal

4 months

Agree! Also if we think in real world for our pts - maintenance HP (esp now we have a subq option) allow pts to not need a port, less frequent labs, less time spent in infusion, more time outside of cancer center Looking forward to hearing pt perspectives! @GRASPtweets @ASCO

Heather Moore

@HeatherMoore16

4 months

Indefinite T-DXd in 1L when patients could otherwise consider maintenance therapies and a chemo free interval is a hard sale. Great review of limitations and needed biomarkers, ongoing trials and overall intention in this patient population by @claudine_isaacs .

0

1

8

Rani Bansal, MD

@DrRaniBansal

4 months

DB-09 📣by @stolaney1 TDxd + P vs THP Great review by Dr. Isaacs of results we need QOL data especially for pts on maintenance HP vs TDxd, we know clinically that there is MUCH more tox w/ TDxd & many pts experience great QOL on HP maintenance therapy @ASCO #bcsm

1

3

9

Rani Bansal, MD

@DrRaniBansal

4 months

1000% agree - @AngieDemichele broke down each point so well and gave great insights on how we should think about this data and its potential limitations in clinical practice right now @ASCO #bcsm

Stephanie Graff, MD, FACP, FASCO

@DrSGraff

4 months

.@AngieDemichele 🔥🔥🔥 #ASCO25 FANTASTIC discussion. Yes to all of this. 🎯

1

4

6

Rani Bansal, MD

@DrRaniBansal

4 months

Key point! Intensive ctDNA screening for every patient when only 10% were eligible to switch? Interested to see the data and discussion later today @ASCO #bcsm

Harold J. Burstein, MD, PhD, FASCO

@DrHBurstein

4 months

1. Intensive ctDNA screening of 10 patients to find 1 who might qualify for 'switching' based on ESR1mut. Worthwhile? 2. Does switching among asymptomatic patients with no radiological progression make sense when drug could be added later at progression?

0

2

Marija Sullivan, MD

@marijasullivan

4 months

Feeling incredibly grateful to be joining this amazing group of breast oncology colleagues at Duke this fall! 💙#ASCO25

2

23

Rani Bansal, MD

@DrRaniBansal

4 months

Our Duke breast onc family at ASCO ❤️ @ASCO @DukeCancer @HeatherMoore16 @CareyAnders1 @marijasullivan

1

4

11

Rani Bansal, MD

@DrRaniBansal

4 months

Dr Kim presented results showing oral paclitaxel vs IV paclitaxel in MBC w/ similar PFS/OS ⭐️differences in SE - more GI tox & neutropenia in PO taxol but less neuropathy and reactions ❗️oral tx regimens for pts means no need for a port, less clinic visits @ASCO #asco25 #bcsm

0

1

4

Rani Bansal, MD

@DrRaniBansal

4 months

Great discussion by Dr Clark @ASCO Some thoughts ⭐️inavo/Palbo/fulv clear 1st line in ET refractory PIK3caM mBC - now w/ sig OS benefit ❓not sure what ipatasertib adds to landscape as Capiversatib seems to have better PFS and OS difference with similar SE profile #ASCO25

1

2